OCV C01

Drug Profile

OCV C01

Alternative Names: C01; OCV-C01

Latest Information Update: 12 Jan 2015

Price : $50

At a glance

  • Originator OncoTherapy Science; Otsuka Pharmaceutical
  • Developer OncoTherapy Science
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 23 Dec 2013 Discontinued - Phase-III for Pancreatic cancer (second-line therapy or greater) in Japan (SC)
  • 29 Jul 2013 Phase-III development for Pancreatic Cancer (second-line therapy or greater) is ongoing in Japan (SC)
  • 02 Nov 2012 Suspended - Phase-III for Pancreatic cancer (second-line therapy or greater) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top